Interleukin-10 and Interleukin-12 modulation in patients with relapsing-remitting Multiple Sclerosis on therapy with interferon-beta 1A: differences in responders and non responders.
- CARRIERI, PIETRO BIAGIO
- POSTIGLIONE, LOREDANA
- Ladogana P.
- Di Spigna G.
- de Leva M. F.
- Petracca M.
- Montella S.
- Buonavolontà L.
- Florio C.
DOIAbstract
We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course
Add to ORKG